Drug Profile

Research programme: SPEAR T cell therapies - Adaptimmune/ Vertex Pharmaceuticals

Alternative Names: Secreted and Transmembrane Immunomodulatory Proteins; SIPs and TIPs

Latest Information Update: 19 Feb 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Adaptimmune; Alpine Immune Sciences
Developer Adaptimmune; Vertex Pharmaceuticals
Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

21 Jul 2021 Preclinical trials in Cancer in USA (Parenteral) (Alpine Immune Sciences pipeline, July 2021)
15 May 2019 Adaptimmune and Alpine Immune Sciences enter into a collaboration and license agreement to develop next-generation SPEAR T-cells for treatment of Cancer
15 May 2019 Early research in Cancer in USA (unspecified route)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com